{"id":"umeclidinium-vilanterol-dry-powder-inhaler","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL1187833","moleculeType":"Small molecule","molecularWeight":"428.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Umeclidinium competitively antagonizes M3 muscarinic receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and promoting smooth muscle relaxation. The dual mechanism provides complementary and sustained airway dilation over 24 hours.","oneSentence":"Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that further dilates airways; together they provide sustained bronchodilation for COPD.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:21.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72},{"nctId":"NCT04937387","phase":"PHASE3","title":"Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-07-29","conditions":"Asthma","enrollment":359},{"nctId":"NCT04923347","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-06-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT05342558","phase":"PHASE4","title":"Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2017-09-19","conditions":"COPD","enrollment":133},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT03611699","phase":"PHASE4","title":"Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients","status":"COMPLETED","sponsor":"Gary L. Pierce","startDate":"2019-01-24","conditions":"COPD","enrollment":15},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT02570165","phase":"PHASE2","title":"Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":325},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT03162055","phase":"PHASE3","title":"Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":1119},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02164513","phase":"PHASE3","title":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10355},{"nctId":"NCT01313650","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1538},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01313637","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1493},{"nctId":"NCT02487446","phase":"PHASE3","title":"Efficacy and Safety Study of QVA149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":357},{"nctId":"NCT02152605","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":498},{"nctId":"NCT01957163","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":619},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01491802","phase":"PHASE3","title":"Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2012-01","conditions":"COPD","enrollment":17},{"nctId":"NCT01521377","phase":"PHASE1","title":"QTc Study GSK573719+GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT01894386","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT02119286","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":620},{"nctId":"NCT02837380","phase":"PHASE1","title":"A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01716520","phase":"PHASE3","title":"Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":182},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anora Ellipta"],"phase":"marketed","status":"active","brandName":"Umeclidinium / Vilanterol Dry Powder Inhaler","genericName":"Umeclidinium / Vilanterol Dry Powder Inhaler","companyName":"Gary L. Pierce","companyId":"gary-l-pierce","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that further dilates airways; together they provide sustained bronchodilation for COPD. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}